Memorial Hospital Research Laboratories
The David Jones Lab
The primary reason people die from cancer is the development of metastatic disease. As a surgeon-scientist who cares for patients with earlier stage lung and esophageal cancer, my laboratory studies why patients with completely resected cancer still develop metastases and die. We have focused a class of genes known as metastasis suppressor genes and, in particular, breast cancer metastasis suppressor I (BRMS1). We have identified important functions of BRMS1 as a transcriptional repressor, an E3 ligase, and a mediator of RelA/p65 transcription in lung cancer. We currently are focused on BRMS1-mediated suppression of metastases in p53mut lung adenocarcinoma (LUAD), as well as the identification of a novel germline point mutation of BRMS1 variant 2 which is actually pro-metastatic. Our lab is also examining tumor genomics in early stage LUAD and has built a comprehensive clinical - and genomically-annotated database for this project. Finally, over the past several years we have established a large patient-derived organoid (PDO) program to explore the biology of metastases and related therapies in vitro and in novel mouse models of metastases. Finally, we have initiated a prospective study examining the role of tumor-related exosomes and extravesical particles in the development of metastases in operable lung cancer patients. Collectively, the goal of my laboratory is to understand the biology of metastases in early-stage lung and esophageal cancer and develop therapies to mitigate this deadly process.
Szymura SJ, Zaemes JP, Allison DF, Clift SH, D’Innocenzi JM, Gray LG, Mckenna BD, morris BB, Bekiranov S, LeGallo RD, Jones DR, Mayo MW. NF-ĸB upregulates glutamine-fructose-6-phosphate transaminase 2 to promote migration in non-small clell lung cancer. Cell Commun Signal 2019;17(1):24.
Forde PM, Chaft JE, Smith KN, Anagnostou V, TCottrell TR, Hellmann MD, Yang SC, Jones DR, Broderick SR, Battafarano R, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Caushi J, Chan HY, Scharpf RB, White J, Gabrielson E, Zahurak M, Rosner G, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018;378:1976-86.
David R. Jones, MD
- Physician-scientist David R. Jones studies molecular mechanisms governing the development of metastases in lung and esophageal cancers.
- AACR Career Development Award for Translational Research in Lung Cancer 2001
- Member, Tumor Progression and Metastases Study Section NCI; 2010-16 (Chair 2014-16)
- Co-Director, Fiona and Stanley Druckenmiller Center for Lung Cancer Research, MSKCC
- Castle Connolly Top Doctors for Cancer 2010-present
To learn more about available postdoctoral opportunities, please visit our Career Center
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
David R. Jones discloses the following relationships and financial interests:
Merck & Co Inc.
Provision of Services (uncompensated)
Shanghai JoAnn Medical Technology Co., Ltd
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.